New combo tackles lung cancer after first drug fails
NCT ID NCT05786430
First seen Feb 01, 2026 · Last updated Jun 19, 2026 · Updated 16 times
Summary
This phase 2 trial tests a combination of the targeted therapy lazertinib plus two chemotherapy drugs (pemetrexed and carboplatin) in 87 adults with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that got worse after prior lazertinib treatment. The main goal is to see how long the cancer stays under control. Participants take lazertinib daily and receive chemo every three weeks for up to four cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lazertinib plus pemetrexed and carboplatin (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with EGFR-mutated lung cancer whose disease has worsened while on lazertinib alone.
What could go wrong
This is a mid-stage trial with only 87 participants, so results may not apply to everyone. Adding chemotherapy also increases side effects like fatigue, nausea, and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.